Brief: Lilly To Acquire Verve Therapeutics To Advance One-Time Treatments For People With High Cardiovascular Risk
17/06/2025 12:33
June 17 (Reuters) - Verve Therapeutics Inc VERV.O: LILLY TO ACQUIRE VERVE THERAPEUTICS TO ADVANCE ONE-TIME TREATMENTS FOR PEOPLE WITH HIGH CARDIOVASCULAR RISK ELI LILLY - PROPOSED DEAL FOR PURCHASE PRICE OF $10.50 PER SHARE IN CASH ELI LILLY - PROPOSED DEAL FOR A TOTAL POTENTIAL CONSIDERATION OF UP TO $13.50 PER SHARE IN CASH WITHOUT INTEREST ELI LILLY - TRANSACTION IS NOT SUBJECT TO ANY FINANCING CONDITION ELI LILLY: CVR HOLDERS WOULD BE ENTITLED TO GET CONTINGENT PAYMENT UPON FIRST PATIENT BEING DOSED WITH VERVE-102 FOR ASCVD IN U.S. PHASE 3 TRIAL Source text: ID:nPn5VQH2Fa Further company coverage: VERV.O ((Reuters.Briefs@thomsonreuters.com;))